Haisco Pharmaceutical Group has signed an exclusive licensing deal with AbbVie, granting AbbVie rights to develop and commercialize new pain treatments globally, excluding China, Hong Kong, and Macau. The agreement covers multiple drug candidates in early development stages. Haisco receives $30 million upfront and can earn up to $715 million in milestone payments plus royalties on sales. This partnership supports Haisco's global expansion and leverages AbbVie's expertise to accelerate innovative pain therapies worldwide.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
